Lentiviral vector ramp-up: J&J and Legend to invest $500M in New Jersey manufacturing to support Carvykti

Zachary Brennan

Senior Editor

In response to a question on manufacturing scale at Legend Biotech’s R&D day yesterday, the company’s top exec said its partnership with Johnson & Johnson …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lentiviral vector ramp-up: J&J and Legend to invest $500M in New Jersey manufacturing to support Carvykti

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Lentivi­ral vec­tor ramp-up: J&J and Leg­end to in­vest $500M in New Jer­sey man­u­fac­tur­ing to sup­port Carvyk­ti

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Lentiviral vector ramp-up: J&J and Legend to invest $500M in New Jersey manufacturing to support Carvykti